A British baby’s death this year after getting Novartis’s gene therapy Zolgensma was not caused by a toxic drug reaction, the Swiss drugmaker said, allaying concerns over the $2.1 million-per-patient treatment’s risks.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc’s over-the-counter nicotine oral spray that aims to help smokers quit their addiction.
For two men trained as scientists, the bosses of Britain’s major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade.
I am a healthcare change catalyst who challenges the status quo in healthcare whilst understanding the world in which healthcare providers and organizations function. I strongly believe that medicine and healthcare are on the cusp of a major transformation driven by new technologies representing an unprecedented opportunity for patient outcome in Asia. I am the Co-Founder and Managing Director of Galen Growth Asia, whose mission it is to foster a sustainable and vibrant HealthTech ecosystem across Asia.